Spiez Laboratory

Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference

Retrieved on: 
Wednesday, October 20, 2021

In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.

Key Points: 
  • In addition, the Company will present a Trial in Progress poster on the EMPATHY clinical trial, conducted in collaboration with Novartis.
  • As such, we must continually test ensovibep against new variants to ensure it has the potential to still be relevant for current and future patients.
  • Finally, viral passaging experiments show ensovibep as comparable to monoclonal antibody cocktails with respect to minimizing the development of escape mutants.
  • Molecular Partners and Novartis are collaborating on the development of ensovibep and are evaluating it in global late-stage study.